Evidence map›Paper›PMID 42539714›Full record

ReviewFrontiers in immunology2026

Inflammation as a master regulator of immunotherapy response in head and neck squamous cell carcinoma: from malignant transformation to ecology-aware precision combinations.

Yingchen Han, Peihong Wu, Haoran Song, Ruoxi Yu, Ruotong Liu, Zhenguang Du, Zhaozhe Liu, Jia Gu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yingchen Han *Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Peihong Wu *Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Haoran Song *Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Ruoxi YuDepartment of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Ruotong LiuShenyang Medical College, Shenyang, Liaoning, China.
Zhenguang DuDepartment of Interventional Medicine, Liaoning Provincial People's Hospital, Shenyang, Liaoning, China.
Zhaozhe LiuDepartment of Oncology, General Hospital of the Northern Theater Command, Shenyang, Liaoning, China.
Jia GuDepartment of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the era of immunotherapy, head and neck squamous cell carcinoma (HNSCC) has demonstrated clear benefits from immune-based treatments and is widely regarded as a tumor type with high immunotherapeutic potential. These tumors are characterized by robust and persistent inflammatory responses that actively drive tumor initiation and progression while concurrently shaping their sensitivity or resistance to therapy. Inflammation simultaneously creates therapeutic vulnerabilities and barriers by altering tumor behavior and reprogramming the immune microenvironment. This review examined HNSCC through a tripartite prism of inflammation, immunity, and tumor biology to demonstrate how chronic inflammatory cues rewire immune cells, reshape signaling circuits, and remodel tissue architecture, ultimately altering responses to immunotherapy. We first examined how immune cell reprogramming occurs under inflammatory pressure. Macrophages, regulatory T cells, exhausted CD8

Indexed as

Cell Transformation, NeoplasticHead and Neck NeoplasmsImmunotherapyInflammationSquamous Cell Carcinoma of Head and NeckAnimalsHumansTumor Microenvironmentcancer-associated fibroblastshead and neck squamous cell carcinomaimmune checkpoint blockadeinflammationmyeloid cellstumor microenvironment

Identifiers

PMID42539714
PMCPMC13424198

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.